Small Interfering RNA (siRNA) Therapeutics Size, Share, and Industry Analysis, By Product (Fitusiran, Patisiran, Givosiran, Lumasiran, Inclisiran, Vutisiran, and Others), By Disease Indication (Hereditary Transthyretin Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 (PH1) Clinical Atherosclerotic Cardiovascular Disease, and Others), By Route of Administration (Intravenous, Subcutaneous, and Others), By Age (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction
   1. Market Scope
   2. Market Segmentation
   3. Market Methodology
   4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities 
   4. Market Trends
4. Key Insights
   1. Pipeline Analysis, By Key Players 
   2. Technological Advancements in the Market
   3. Regulatory and Reimbursement Scenario, by Key Countries/ Regions
   4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
5. Global Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Product
      1. Fitusiran
      2. Patisiran
      3. Givosiran
      4. Lumasiran
      5. Inclisiran
      6. Vutisiran
      7. Others 
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Hereditary Transthyretin Amyloidosis (hATTR)
      2. Acute Hepatic Porphyria (AHP)
      3. Primary Hyperoxaluria Type 1 (PH1) 
      4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
      5. Others 
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous 
      3. Others
   4. Market Analysis, Insights and Forecast – By Age
      1. Pediatrics
      2. Adults
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies 
   6. Market Analysis, Insights and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
6. North America Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Product
      1. Fitusiran
      2. Patisiran
      3. Givosiran
      4. Lumasiran
      5. Inclisiran
      6. Vutisiran
      7. Others 
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Hereditary Transthyretin Amyloidosis (hATTR)
      2. Acute Hepatic Porphyria (AHP)
      3. Primary Hyperoxaluria Type 1 (PH1) 
      4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
      5. Others 
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous 
      3. Others
   4. Market Analysis, Insights and Forecast – By Age
      1. Pediatrics
      2. Adults
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
   6. Market Analysis, Insights and Forecast – By Country
      1. U.S. 
      2. Canada 
7.  Europe Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Product
      1. Fitusiran
      2. Patisiran
      3. Givosiran
      4. Lumasiran
      5. Inclisiran
      6. Vutisiran
      7. Others 
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Hereditary Transthyretin Amyloidosis (hATTR)
      2. Acute Hepatic Porphyria (AHP)
      3. Primary Hyperoxaluria Type 1 (PH1) 
      4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
      5. Others 
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous 
      3. Others
   4. Market Analysis, Insights and Forecast – By Age
      1. Pediatrics
      2. Adults
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. U.K.
      2. Germany
      3. France
      4. Spain
      5. Italy
      6. Scandinavia
      7. Rest of Europe 
8. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Product
      1. Fitusiran
      2. Patisiran
      3. Givosiran
      4. Lumasiran
      5. Inclisiran
      6. Vutisiran
      7. Others 
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Hereditary Transthyretin Amyloidosis (hATTR)
      2. Acute Hepatic Porphyria (AHP)
      3. Primary Hyperoxaluria Type 1 (PH1) 
      4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
      5. Others 
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous 
      3. Others
   4. Market Analysis, Insights and Forecast – By Age
      1. Pediatrics
      2. Adults
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Japan
      2. China
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific 
9. Latin America Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Product
      1. Fitusiran
      2. Patisiran
      3. Givosiran
      4. Lumasiran
      5. Inclisiran
      6. Vutisiran
      7. Others 
   2. Market Analysis, Insights and Forecast – By Disease Indication
      1. Hereditary Transthyretin Amyloidosis (hATTR)
      2. Acute Hepatic Porphyria (AHP)
      3. Primary Hyperoxaluria Type 1 (PH1) 
      4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
      5. Others 
   3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Intravenous
      2. Subcutaneous 
      3. Others
   4. Market Analysis, Insights and Forecast – By Age
      1. Pediatrics
      2. Adults
   5. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies 
      2. Drug Stores & Retail Pharmacies
      3. Online Pharmacies
   6. Market Analysis, Insights and Forecast – By Country/Sub-region
      1. Brazil 
      2. Mexico 
      3. Rest of Latin America
10. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Product
       1. Fitusiran
       2. Patisiran
       3. Givosiran
       4. Lumasiran
       5. Inclisiran
       6. Vutisiran
       7. Others 
    2. Market Analysis, Insights and Forecast – By Disease Indication
       1. Hereditary Transthyretin Amyloidosis (hATTR)
       2. Acute Hepatic Porphyria (AHP)
       3. Primary Hyperoxaluria Type 1 (PH1) 
       4. Clinical Atherosclerotic Cardiovascular Disease (ASCVD) 
       5. Others 
    3. Market Analysis, Insights and Forecast – By Route of Administration
       1. Intravenous
       2. Subcutaneous 
       3. Others
    4. Market Analysis, Insights and Forecast – By Age
       1. Pediatrics
       2. Adults
    5. Market Analysis, Insights and Forecast – By Distribution Channel
       1. Hospital Pharmacies 
       2. Drug Stores & Retail Pharmacies
       3. Online Pharmacies
    6. Market Analysis, Insights and Forecast – By Country/Sub-region
       1. South Africa
       2. GCC 
       3. Rest of Middle East & Africa
11. Competitive Analysis
    1. Global Market Share Analysis (2024)
    2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
       1. Alnylam Pharmaceuticals, Inc. 
       2. AbbVie Inc. 
       3. Boehringer Ingelheim International GmbH. 
       4. Novo Nordisk A/S 
       5. Novartis AG
       6. Sirnaomics 
       7. Regeneron Pharmaceuticals Inc
       8. Arrowhead Pharmaceuticals, Inc.